Thursday, Scorpius Holdings Inc (NYSE:SCPX) released preliminary financial results for the fourth quarter of 2023.
Scorpius Holdings is an integrated large molecule contract development and manufacturing organization (CDMO) focused on advancing biologic and cell therapy programs.
Scorpius offers analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies.
The company anticipates fourth-quarter 2023 revenue of $3.4 million-$3.6 million, a 375% sequential increase reflecting the completion of contract milestones primarily in the microbial facility and process development work.
Additionally, the company projects that its operating loss will …
Leave a Reply